The role of clinical trials study coordinator (SC) in the era of theragnosis in neuroendocrine tumors (NETs): Challenges and opportunities

#3236

Introduction: Since new radiopharmaceuticals have emerged as cancer treatment, Lutecium177 in NET, and Radium-223 in prostate cancer, there has been an increase in clinical trials (CT) based on theragnosis. This scenario represents an organizational challenge to the coordination of nuclear medicine (NM), radiopharmacy (RP), and medical oncology (MO).

Aim(s): In this study, we review some of the challenges related with patient inclusion in theragnosis CTs and the role of SC as a central part of them.

Materials and methods: All active CT in NET in our center between 2015 and 2020 were reviewed by the CT Unit, MO and NM. Studies related to theragnosis were selected for analysis, and the four CT not related to theragnosis with the highest recruitment were selected as the control group to measure the length of the screening period. In addition, challenges and complexities in the clinical, logistic, and organizative fields were identified as areas of improvement.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Perera J, Fernández I, Hernando J, Pérez C, Serra J,

Keywords: radiopharmaceuticals, NET, neuroendocrine tumor, theragnosis, radiopharmacy, medical oncology, nuclear medicine, Lutecium177, Radium-223, study coordinator, screening period, challenges and opportunities,